SYSTANE® PRO
DrugSYSTANE® PRO is a preservative free artificial tear with a unique triple action formula that contains hyaluronate, nano-sized lipids, and HP-Guar.
NCT Number: NCT07243275
This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-inferior to MIEBO™ after one month of treatment, based on change in Ocular Surface Disease Index (OSDI) scores.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 4
Eye Research Foundation, Newport Beach, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SYSTANE® PRO is a preservative free artificial tear with a unique triple action formula that contains hyaluronate, nano-sized lipids, and HP-Guar.
Perfluorohexyloctane (PFHO) ophthalmic solution, which is marketed in the United States as MIEBO™ (Bausch + Lomb; Rochester, NY, USA) is a preservative-free eye drop.
Time frame: Between group difference at 1 month
Between-group difference in mean change from baseline in Ocular Surface Disease Index (OSDI) Scores at the 1-month visit (0-100 scale).
Contact information is provided by the study sponsor or research team.
Indiana University
Other
Comparing the Efficacy of SYSTANE® PRO to MIEBO™ for the Treatment of Dry Eye Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07732010
Dry Eye Disease (DED), Dry Eye Syndromes
New York, United States
View Trial DetailsNCT07548632
Dry Eye Disease (DED), Dry Eye Syndromes
Aliso Viejo, California, United States
View Trial DetailsNCT07656688
Dry Eye Disease (DED), Dry Eye Syndromes
Seoul, South Korea
View Trial DetailsNCT07676084
Dry Eye Disease (DED), Dry Eye Syndromes
Andover, Massachusetts, United States
View Trial Details